PROMOTE Study: Prediction of Response Of HorMOnal Treatment in Advanced and Recurrent Endometrial Cancer
Trial statusRecruiting
Trial phaseNot listed
Trial typeObservational
Biological sexFemale
Age18-110
SponsorRadboud University Medical Center
About this trial
The PROMOTE study aims at optimising use of hormonal therapy in advanced stage and recurrent endometrial cancer analysing tumor tissue taken before start of hormonal therapy
Eligibility criteria
Qualifiers
Advanced stage (FIGO stage III and IV) and recurrent endometrial cancer
All histologic types of endometrial carcinoma
Planned treatment with any type of hormonal therapy
Biopsy taken within 120 days prior to start of hormonal therapy with no intercurrent therapy between biopsy and start of hormonal therapy.
Disqualifiers
Adjuvant hormonal therapy started following complete resection of endometrial carcinoma
Synchronous use of hormonal therapy for other indications
Endometrial sarcoma or endometrial stroma cell sarcoma
Trial design
Treatments tested in this trial
- Hormonal Antineoplastics
Treatment groups
150 Participants
are divided into 1 treatment groupSponsors and collaborators
Radboud University Medical Center
Lead sponsor
Haukeland University Hospital
Collaborator
Maastricht University Medical Center
Collaborator
Brno University Hospital
Collaborator
Holycross Cancer Center Kielce
Collaborator
Medical University of Lublin
Collaborator
Hospital del Mar
Collaborator
Hospital Vall d'Hebron
Collaborator
Royal Cornwall Hospitals Trust
Collaborator
Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)
Collaborator
The Netherlands Cancer Institute
Collaborator
Canisius-Wilhelmina Hospital
Collaborator
Catharina Ziekenhuis Eindhoven
Collaborator
Erasmus Medical Center
Collaborator
Leiden University Medical Center
Collaborator
Source ClinicalTrials.gov